Cargando…

Improving visual acuity with nivolumab plus ipilimumab plus two cycles of chemotherapy following a diagnosis of lung adenocarcinoma with choroidal metastasis: A case report and literature review

A 75‐year‐old woman presented at our hospital with bilateral visual impairment. Ophthalmological examination revealed multiple choroidal tumours. Chest computed tomography revealed a tumour shadow in the right lower lobe and multiple lymph node metastases in the mediastinum and pulmonary hilum. Foll...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsuyama, Takahiro, Oniwa, Masashi, Tsuruzono, Kentaro, Yasuda, Shunsuke, Yone, Mikiko, Tomioka, Yuya, Uchida, Akifumi, Mitsuyama, Hideo, Kubota, Shingo, Suetsugu, Takayuki, Mizuno, Keiko, Inoue, Hiromasa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2023
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687591/ https://www.ncbi.nlm.nih.gov/pubmed/38045825 http://dx.doi.org/10.1002/rcr2.1262

Ejemplares similares

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
por: Shitara, Kohei, et al.
Publicado: (2022)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma
por: Numakura, Kazuyuki, et al.
Publicado: (2023)

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
por: Glutsch, Valerie, et al.
Publicado: (2021)

The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases
por: Fukumoto, Takeshi, et al.
Publicado: (2022)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
por: Zhou, Shi, et al.
Publicado: (2019)

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
por: Reuss, Joshua E, et al.
Publicado: (2020)

Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC
por: Luo, Yuejun, et al.
Publicado: (2022)

Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma
por: Pedersen, Jesper Geert, et al.
Publicado: (2022)

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2018)

Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
por: Yang, Yi, et al.
Publicado: (2020)

Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis
por: Serritella, Anthony V., et al.
Publicado: (2023)

Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date
por: Remon, Jordi, et al.
Publicado: (2019)

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
por: Najjar, Yana G, et al.
Publicado: (2020)

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
por: Yoshida, Saaya, et al.
Publicado: (2019)

Safe administration of ipilimumab plus nivolumab to a dialysis patient with renal cell carcinoma
por: Iwaki, Takuya, et al.
Publicado: (2020)

Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab
por: Fuchizawa, Hirotaka, et al.
Publicado: (2021)

Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma
por: Kraehenbuehl, Lukas, et al.
Publicado: (2022)

Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations
por: Vázquez-Montero, Lucía, et al.
Publicado: (2023)

Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy
por: Nishimura, Tomoka, et al.
Publicado: (2022)

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
por: Wu, Bin, et al.
Publicado: (2018)

Correction: Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
Publicado: (2020)

Severe Demyelinating Neuropathy in an Advanced Melanoma Patient Treated with Nivolumab plus Ipilimumab Combined Therapy
por: Kambayashi, Yumi, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
por: Wan, Xiaomin, et al.
Publicado: (2021)

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
por: Yang, Liu, et al.
Publicado: (2023)

Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
por: Watson, Tina R., et al.
Publicado: (2020)

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer
por: Boudadi, Karim, et al.
Publicado: (2018)

Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report
por: Appelbaum, Jacob, et al.
Publicado: (2018)

Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
por: Quon, Peter L., et al.
Publicado: (2019)

Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
por: Yang, Szu-Chun, et al.
Publicado: (2021)

Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients
por: Salaün, Hélène, et al.
Publicado: (2022)

Impact of Bone Metastases on Patients with Renal Cell Carcinoma or Melanoma Treated with Combotherapy Ipilimumab Plus Nivolumab
por: Pham, Félix, et al.
Publicado: (2022)

A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma(☆)
por: Tarhini, A.A., et al.
Publicado: (2021)

Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland
por: Barbier, Michaela Carla, et al.
Publicado: (2023)

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis
por: Chen, Jingjie, et al.
Publicado: (2020)

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma
por: Tucker, Matthew D., et al.
Publicado: (2021)

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
por: Motzer, Robert J, et al.
Publicado: (2022)

Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non–small-cell Lung Cancer
por: Hao, Xuezhi, et al.
Publicado: (2021)

Combination immunotherapy of nivolumab plus ipilimumab in a lung cancer patient with Werner syndrome; a case report
por: Ikematsu, Yuki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ngehn68p9oo454g50qequgaq9c